BR112022023368A2 - Elafibranor para o tratamento de colangite esclerosante primária - Google Patents

Elafibranor para o tratamento de colangite esclerosante primária

Info

Publication number
BR112022023368A2
BR112022023368A2 BR112022023368A BR112022023368A BR112022023368A2 BR 112022023368 A2 BR112022023368 A2 BR 112022023368A2 BR 112022023368 A BR112022023368 A BR 112022023368A BR 112022023368 A BR112022023368 A BR 112022023368A BR 112022023368 A2 BR112022023368 A2 BR 112022023368A2
Authority
BR
Brazil
Prior art keywords
elafibranor
treatment
sclerosing cholangitis
primary sclerosing
cholangitis
Prior art date
Application number
BR112022023368A
Other languages
English (en)
Inventor
Roudot Alice
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of BR112022023368A2 publication Critical patent/BR112022023368A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

ELAFIBRANOR PARA O TRATAMENTO DE COLANGITE ESCLEROSANTE PRIMÁRIA. A presente invenção se refere a elafibranor ou seu metabólito ativo para uso em um método de tratamento de colangite esclerosante primária.
BR112022023368A 2020-05-18 2021-05-18 Elafibranor para o tratamento de colangite esclerosante primária BR112022023368A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305513 2020-05-18
PCT/EP2021/063075 WO2021233874A1 (en) 2020-05-18 2021-05-18 Elafibranor for the treatment of primary sclerosing cholangitis

Publications (1)

Publication Number Publication Date
BR112022023368A2 true BR112022023368A2 (pt) 2022-12-20

Family

ID=71465234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023368A BR112022023368A2 (pt) 2020-05-18 2021-05-18 Elafibranor para o tratamento de colangite esclerosante primária

Country Status (12)

Country Link
US (1) US20230165821A1 (pt)
EP (1) EP4153156A1 (pt)
JP (1) JP2023526410A (pt)
KR (1) KR20230011958A (pt)
CN (1) CN115605192A (pt)
AU (1) AU2021275381A1 (pt)
BR (1) BR112022023368A2 (pt)
CA (1) CA3176020A1 (pt)
IL (1) IL297436A (pt)
MX (1) MX2022014364A (pt)
TW (1) TW202207911A (pt)
WO (1) WO2021233874A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
FR2902789A1 (fr) * 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
CN114796237B (zh) * 2016-03-31 2024-02-23 基恩菲特公司 胆汁淤积性疾病的治疗方法
FR3056909B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists

Also Published As

Publication number Publication date
US20230165821A1 (en) 2023-06-01
MX2022014364A (es) 2022-12-15
CN115605192A (zh) 2023-01-13
AU2021275381A1 (en) 2022-11-24
KR20230011958A (ko) 2023-01-25
JP2023526410A (ja) 2023-06-21
CA3176020A1 (en) 2021-11-25
TW202207911A (zh) 2022-03-01
WO2021233874A1 (en) 2021-11-25
EP4153156A1 (en) 2023-03-29
IL297436A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CO2018012894A2 (es) Derivados de pirazol como inhibidores de calicreína plasmática
BR112018000635A2 (pt) compostos aza substituídos como inibidores irak-4
EA201892625A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
EA201892510A2 (ru) Комбинированная терапия для лечения рака
BR112015020941A2 (pt) uso de derivados de pirazolopirimidina para o tratamento de distúrbios relacionados a pi3kdelta
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112017009552A2 (pt) métodos para alvejar o controle transcricional em regiões de super-realçador
CO2022000481A2 (es) Inhibidores de enzimas
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
BR112015006037A2 (pt) métodos para tratamento de hcv
BR112013026327A2 (pt) inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia
BR112013005792A2 (pt) método para o tratamento concomitante de teofilina e febuxostat
BR112018015386A2 (pt) uso de moduladores de receptor gabaa para tratamento de prurido
ECSP22094536A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112022020643A2 (pt) Método de tratamento de esteato-hepatite não alcoólica
BR112017025263A2 (pt) método para o tratamento de doença neurológica
BR112022001393A2 (pt) Forma cristalina do inibidor de atr e seu uso
BR112019008241A2 (pt) tratamento do prurigo nodular
CO2022000270A2 (es) Inhibidores de enzimas
BR112023000675A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
CL2022000214A1 (es) Inhibidores de enzimas